Stock Price Forecast

May 2, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading PLx Pharma Inc. chart...

About the Company

PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.

CEO

Ronald Zimmerman

Exchange

NASDAQ

$9M

Total Revenue

19

Employees

$0M

Market Capitalization

-0.01

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PLXP News

PLx Pharma Inc. Common Stock (PLXP)

6y ago, source: Nasdaq

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Why Is PLx Pharma (PLXP) Stock Down 32% Today?

1y ago, source: Hosted on MSN

PLx Pharma (NASDAQ:PLXP) stock continues to fall on Wednesday as the company gets closer to being delisted from the Nasdaq. An update from PLx Pharma revealed that the Nasdaq is not giving it ...

PLX Protalix BioTherapeutics, Inc.

2d ago, source: Seeking Alpha

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx ...

PLX Inc

4y ago, source: Optics

PLX Inc. is a state-of-the-art optical solutions provider and the leader in development and fabrication of monolithic and invariant optics, and the pioneers of hollow retroreflectors, such as the ...

Robert G. Shawah's Net Worth

21d ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include PLx Pharma Inc., AMERI Holdings, Inc., and Acurx Pharmaceuticals, Inc..

Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels

3mon ago, source: ADVFN

PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard ...

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript

1mon ago, source: Hosted on MSN

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript March 14, 2024 Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations ...

Cocrystal Pharma Stock (NASDAQ:COCP), Quotes and News Summary

3y ago, source: Benzinga.com

Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers PLx Pharma Inc. (NASDAQ: PLXP) gained 128.2% to $0.2399 after dropping over 13% on Thursday. Lisa Levin $2M Bet On Cocrystal Pharma?

HOOK HOOKIPA Pharma Inc.

1d ago, source: Seeking Alpha

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s ...

Protalix BioTherapeutics, Inc. (PLX)

4d ago, source: Yahoo Finance

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its ...

Protalix BioTherapeutics, Inc. (PLX)

1y ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Protalix BioTherapeutics, Inc. (PLX)

5y ago, source: Yahoo Finance

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript March 14, 2024 Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...